Odermatt A, Dick B, Arnold P, Zaehner T, Plueschke V, Deregibus M N, Repetto H, Frey B M, Frey F J, Ferrari P
Division of Nephrology and Hypertension, Inselspital, University of Berne, 3010 Berne, Switzerland.
J Clin Endocrinol Metab. 2001 Mar;86(3):1247-52. doi: 10.1210/jcem.86.3.7334.
Renal 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) is an enzyme responsible for the peripheral inactivation of cortisol to cortisone in mineralocorticoid target tissues. Mutations in the gene encoding 11betaHSD2 cause the syndrome of apparent mineralocorticoid excess (AME), an autosomal recessive form of inherited hypertension, in which cortisol acts as a potent mineralocorticoid. The mutations reported to date have been confined to exons 3-5. Here, we describe two siblings, 1 and 2 yr old, who were diagnosed with hypokalemic hypertension and low plasma aldosterone and renin levels, indicating mineralocorticoid hypertension. Analysis of urinary steroid metabolites showed a markedly impaired metabolism of cortisol, with (tetrahydrocortisol + 5alpha-tetrahydrocortisol)/tetrahydrocortisone ratios of 40-60, and nearly absent urinary free cortisone. Although phenotypically normal, the heterozygous parents showed a disturbed cortisol metabolism. Genetic analysis of the HSD11B2 gene from the AME patients revealed the homozygous deletion of six nucleotides in exon 2 with the resultant loss of amino acids Leu(114) and Glu(115), representing the first alteration found in the cofactor-binding domain. The deletion mutant, expressed in HEK-293 cells, showed an approximately 20-fold lower maximum velocity but increased apparent affinity for cortisol and corticosterone. In contrast, two additionally constructed substitutions, Glu(115) to Gln or Lys, showed increased maximal velocity and apparent affinity for 11beta-hydroxyglucocorticoids. Functional analysis of wild-type and mutant proteins indicated that a disturbed conformation of the cofactor-binding domain, but not the missing negative charge of Glu(115), led to the observed decreased activity of the deletion mutant. Considered together, these findings provide evidence for a role of Glu(115) in determining cofactor-binding specificity of 11betaHSD2 and emphasize the importance of structure-function analysis to elucidate the molecular mechanism of AME.
肾11β-羟类固醇脱氢酶2型(11βHSD2)是一种负责在盐皮质激素靶组织中将皮质醇外周失活转化为可的松的酶。编码11βHSD2的基因突变会导致表观盐皮质激素增多症(AME),这是一种常染色体隐性遗传形式的高血压,其中皮质醇起着强效盐皮质激素的作用。迄今为止报道的突变局限于外显子3至5。在此,我们描述了两名分别为1岁和2岁的同胞,他们被诊断为低钾血症性高血压,血浆醛固酮和肾素水平较低,提示盐皮质激素性高血压。尿类固醇代谢产物分析显示皮质醇代谢明显受损,(四氢皮质醇 + 5α-四氢皮质醇)/四氢可的松比值为40至60,且尿游离可的松几乎缺失。尽管父母表型正常,但杂合子父母显示出皮质醇代谢紊乱。对AME患者的HSD11B2基因进行遗传分析发现,外显子2中有六个核苷酸的纯合缺失,导致亮氨酸(Leu114)和谷氨酸(Glu115)氨基酸缺失,这是在辅因子结合域中发现的首个改变。在HEK-293细胞中表达的缺失突变体显示最大速度降低约20倍,但对皮质醇和皮质酮的表观亲和力增加。相反,另外构建的两个替换突变体,即谷氨酸(Glu115)突变为谷氨酰胺或赖氨酸,显示出最大速度增加以及对11β-羟基糖皮质激素的表观亲和力增加。野生型和突变型蛋白的功能分析表明,辅因子结合域构象紊乱,而非谷氨酸(Glu115)负电荷缺失,导致观察到的缺失突变体活性降低。综合考虑,这些发现为谷氨酸(Glu115)在决定11βHSD2辅因子结合特异性中的作用提供了证据,并强调了结构-功能分析对阐明AME分子机制的重要性。